ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.
Abstract
Age-related macular degeneration (AMD) is a major leading cause of irreversible visual
impairment in the world with limited therapeutic interventions. Histological, biochemical,
genetic, and epidemiological studies strongly implicate dysregulated lipid metabolism
in the retinal pigmented epithelium (RPE) in AMD pathobiology. However, effective
therapies targeting lipid metabolism still need to be identified and developed for
this blinding disease. To test lipid metabolism-targeting therapies, preclinical AMD
mouse models are needed to establish therapeutic efficacy and the role of lipid metabolism
in the development of AMD-like pathology. In this review, we provide a comprehensive
overview of current AMD mouse models available to researchers that could be used to
provide preclinical evidence supporting therapies targeting lipid metabolism for AMD.
Based on previous studies of AMD mouse models, we discuss strategies to modulate lipid
metabolism as well as examples of studies evaluating lipid-targeting therapeutics
to restore lipid processing in the RPE. The use of AMD mouse models may lead to worthy
lipid-targeting candidate therapies for clinical trials to prevent the blindness caused
by AMD.
Type
Journal articleSubject
age-related macular degenerationcomplement
lipid metabolism
mouse models
retinal pigmented epithelium
therapeutics
Permalink
https://hdl.handle.net/10161/24022Published Version (Please cite this version)
10.1089/jop.2021.0067Publication Info
(2021). Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration:
Insights from Preclinical Mouse Models. J Ocul Pharmacol Ther. 10.1089/jop.2021.0067. Retrieved from https://hdl.handle.net/10161/24022.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Catherine Bowes Rickman
George and Geneva Boguslavsky Distinguished Professor of Eye Research
Dr. Bowes Rickman is a highly accomplished translational scientist whose research
efforts over two decades have been focused on the molecular/cell biology and pathobiology
of age-related macular degeneration (AMD). In an effort to better understand the pathophysiology
of AMD, she has created a number of murine models that recapitulate many aspects of
human AMD and point the way toward eventual treatments for AMD. Among many cited seminal
contributions is her discovery of a connection betwee
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info